Opsumit shows real-world safety, efficacy for CTD-PAH patients

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

Janssen stops Phase 3 trial testing high-dose Opsumit in CTEPH

A Phase 3 clinical trial testing high-dose Opsumit (macitentan) in people with chronic thromboembolic pulmonary hypertension (CTEPH) has ended early after an analysis showed the treatment is unlikely to help patients. The announcement was made in a press release from Janssen, the company that markets Opsumit. Opsumit…

Study Gauges Long-term Survival for PAH Patients on Opsumit

More than half of people with pulmonary arterial hypertension (PAH) who start daily treatment with oral Opsumit (macitentan) are expected to still be alive after nine years on the therapy, according to a new analysis of data from the SERAPHIN clinical trial and its open-label extension. “These analyses…

Opsynvi, Macitentan Plus Tadalafil, Approved in Canada for PAH

Opsynvi, a fixed-dose oral combination of macitentan and tadalafil, was approved by Health Canada for the long-term treatment of pulmonary arterial hypertension (PAH). It is for use by patients on stable doses of its two active compounds: macitentan (sold as Opsumit) at 10 mg and tadalafil (sold as Adcirca) at 40 mg. Marketed…

CAR Peptide Improves Remodulin Efficacy in PH Rat Model

CAR peptide (CAR), Vascular BioSciences’ lead therapeutic peptide candidate for pulmonary hypertension (PH) and other disorders, was found to increase the efficacy of Remodulin (treprostinil) at reducing clinical signs of PH and prolonging the survival of a rat model of the disease. These preclinical findings were…

Top 10 Pulmonary Hypertension Stories of 2019

Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…